Biologics

Regenerative medicine company CollPlant appointed Jonathan M.N. Rigby as chairman of the board of directors.

Ortho Regenerative Technologies published the results of two scientific studies validating its product's ability to improve the repair of rotator cuff tendon and articular cartilage tissue.

The Pacific Brain Tumor Center at Santa Monica, Calif.-based Pacific Neuroscience Institute will serve as the leading enrollment site for Medicenna Therapeutics' clinical trial.

ThermoGenesis Corp. entered into a supply agreement with Los Angeles-based Orthohealing Center Management.

The CDC is investigating bacterial infections in patients who received stem cell treatments from the ReGen Series, distributed by Liveyon.

The global spine biologics market is expected to reach $2.7 billion by 2024, increasing at a 4.4 percent compound annual growth rate, according to a Data Bridge Market Research report.

Judge Brouck Jacobs ordered the Columbia-based University of Missouri to comply with a discovery request of its biojoint surgery records, according to the Columbia Tribune.

Japan approved Stemirac, a stem cell treatment for spinal cord injuries, Nature reports.

Asterias Biotherapeutics conducted a clinical trial to study the effectiveness of its OPC1 cells, Seeking Alpha reports. The company released its one-year results.

The American Association of Hip and Knee Surgeons does not currently recommend biologic treatments for advanced hip or knee arthritis, according to a new position statement.